Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
673 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Psoriasis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H2 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape. Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up skin, itchiness, and burning sensation, swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Psoriasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Psoriasis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Psoriasis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 19, 1, 20, 44, 44, 2, 106, 30 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 6 molecules, respectively. Psoriasis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Psoriasis (Immunology). - The pipeline guide reviews pipeline therapeutics for Psoriasis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Psoriasis (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Psoriasis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Psoriasis (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Psoriasis (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Psoriasis (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 Introduction 8 Psoriasis - Overview 9 Psoriasis - Therapeutics Development 10 Psoriasis - Therapeutics Assessment 41 Psoriasis - Companies Involved in Therapeutics Development 57 Psoriasis - Drug Profiles 120 Psoriasis - Dormant Projects 613 Psoriasis - Discontinued Products 629 Psoriasis - Product Development Milestones 632 Appendix 644
List of Tables
Number of Products under Development for Psoriasis, H2 2017 38 Number of Products under Development by Companies, H2 2017 40 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 41 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 42 Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 43 Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 44 Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 45 Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 46 Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 47 Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 48 Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 49 Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 50 Number of Products under Development by Universities/Institutes, H2 2017 51 Products under Development by Companies, H2 2017 52 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 53 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 54 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 55 Products under Development by Companies, H2 2017 (Contd..4), H2 2017 56 Products under Development by Companies, H2 2017 (Contd..5), H2 2017 57 Products under Development by Companies, H2 2017 (Contd..6), H2 2017 58 Products under Development by Companies, H2 2017 (Contd..7), H2 2017 59 Products under Development by Companies, H2 2017 (Contd..8), H2 2017 60 Products under Development by Companies, H2 2017 (Contd..9), H2 2017 61 Products under Development by Companies, H2 2017 (Contd..10), H2 2017 62 Products under Development by Companies, H2 2017 (Contd..11), H2 2017 63 Products under Development by Companies, H2 2017 (Contd..12), H2 2017 65 Products under Development by Companies, H2 2017 (Contd..13), H2 2017 66 Products under Development by Companies, H2 2017 (Contd..14), H2 2017 67 Products under Development by Universities/Institutes, H2 2017 68 Number of Products by Stage and Target, H2 2017 70 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 71 Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 72 Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 73 Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 74 Number of Products by Stage and Mechanism of Action, H2 2017 76 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 77 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 78 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 79 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 80 Number of Products by Stage and Route of Administration, H2 2017 82 Number of Products by Stage and Molecule Type, H2 2017 84 Psoriasis - Pipeline by 3SBio Inc, H2 2017 85 Psoriasis - Pipeline by AbbVie Inc, H2 2017 86 Psoriasis - Pipeline by Abeome Corp, H2 2017 86 Psoriasis - Pipeline by AbGenomics International Inc, H2 2017 86 Psoriasis - Pipeline by Adello Biologics LLC, H2 2017 87 Psoriasis - Pipeline by Affibody AB, H2 2017 87 Psoriasis - Pipeline by Albireo Pharma Inc, H2 2017 88 Psoriasis - Pipeline by Alfacyte Ltd, H2 2017 88 Psoriasis - Pipeline by Allergan Plc, H2 2017 88 Psoriasis - Pipeline by Almirall SA, H2 2017 89 Psoriasis - Pipeline by Alteogen Inc, H2 2017 89 Psoriasis - Pipeline by Amgen Inc, H2 2017 90 Psoriasis - Pipeline by AnaptysBio Inc, H2 2017 90 Psoriasis - Pipeline by ApoPharma Inc, H2 2017 91 Psoriasis - Pipeline by Arbor Pharmaceuticals LLC, H2 2017 91 Psoriasis - Pipeline by Arrien Pharmaceuticals LLC, H2 2017 91 Psoriasis - Pipeline by AstraZeneca Plc, H2 2017 92 Psoriasis - Pipeline by Athenex Inc, H2 2017 92 Psoriasis - Pipeline by Atlantic Bio Sci LLC, H2 2017 93 Psoriasis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2017 93 Psoriasis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2017 94 Psoriasis - Pipeline by Baliopharm AG, H2 2017 94 Psoriasis - Pipeline by Bayer AG, H2 2017 94 Psoriasis - Pipeline by Beta Pharma Inc, H2 2017 95 Psoriasis - Pipeline by BioApex sro, H2 2017 95 Psoriasis - Pipeline by Biocad, H2 2017 96 Psoriasis - Pipeline by Biocon Ltd, H2 2017 96 Psoriasis - Pipeline by BioLingus AG, H2 2017 97 Psoriasis - Pipeline by Bionomics Ltd, H2 2017 97 Psoriasis - Pipeline by Bionovis SA, H2 2017 97 Psoriasis - Pipeline by BirchBioMed Inc, H2 2017 98 Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H2 2017 98 Psoriasis - Pipeline by Brickell Biotech Inc, H2 2017 99 Psoriasis - Pipeline by Bristol-Myers Squibb Company, H2 2017 99 Psoriasis - Pipeline by C4X Discovery Holdings PLC, H2 2017 100 Psoriasis - Pipeline by CalciMedica Inc, H2 2017 100 Psoriasis - Pipeline by Can-Fite BioPharma Ltd, H2 2017 100 Psoriasis - Pipeline by Celgene Corp, H2 2017 101 Psoriasis - Pipeline by ChemoCentryx Inc, H2 2017 101 Psoriasis - Pipeline by Chipscreen Biosciences Ltd, H2 2017 102 Psoriasis - Pipeline by ChironWells GmbH, H2 2017 102 Psoriasis - Pipeline by Coherus BioSciences Inc, H2 2017 103 Psoriasis - Pipeline by Compugen Ltd, H2 2017 103 Psoriasis - Pipeline by Concenter BioPharma Silkim Ltd, H2 2017 103 Psoriasis - Pipeline by conoGenetix biosciences GmbH, H2 2017 104 Psoriasis - Pipeline by Crescita Therapeutics Inc, H2 2017 104 Psoriasis - Pipeline by Dermala Inc, H2 2017 105 Psoriasis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017 105 Psoriasis - Pipeline by DURECT Corp, H2 2017 106 Psoriasis - Pipeline by EA Pharma Co Ltd, H2 2017 106 Psoriasis - Pipeline by Eli Lilly and Company, H2 2017 106 Psoriasis - Pipeline by ELORAC Inc, H2 2017 107 Psoriasis - Pipeline by Exicure Inc, H2 2017 107 Psoriasis - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 108 Psoriasis - Pipeline by Formycon AG, H2 2017 108 Psoriasis - Pipeline by Forward Pharma AS, H2 2017 109 Psoriasis - Pipeline by Fresenius SE & Co KGaA, H2 2017 109 Psoriasis - Pipeline by Galapagos NV, H2 2017 110 Psoriasis - Pipeline by Galderma SA, H2 2017 110 Psoriasis - Pipeline by Galectin Therapeutics Inc, H2 2017 110 Psoriasis - Pipeline by Gem Pharmaceuticals LLC, H2 2017 111 Psoriasis - Pipeline by Genentech Inc, H2 2017 111 Psoriasis - Pipeline by Genfit SA, H2 2017 112 Psoriasis - Pipeline by Genor BioPharma Co Ltd, H2 2017 112 Psoriasis - Pipeline by GlaxoSmithKline Plc, H2 2017 113 Psoriasis - Pipeline by GlycoMar Ltd, H2 2017 113 Psoriasis - Pipeline by Grupo Ferrer Internacional SA, H2 2017 113 Psoriasis - Pipeline by HitGen LTD, H2 2017 114 Psoriasis - Pipeline by Huabo Biopharm Co Ltd, H2 2017 114 Psoriasis - Pipeline by Hydra Biosciences Inc, H2 2017 114 Psoriasis - Pipeline by iCo Therapeutics Inc., H2 2017 115 Psoriasis - Pipeline by Immune Pharmaceuticals Inc, H2 2017 115 Psoriasis - Pipeline by Immune Response BioPharma Inc, H2 2017 116 Psoriasis - Pipeline by Immungenetics AG, H2 2017 116 Psoriasis - Pipeline by Immunwork Inc, H2 2017 116 Psoriasis - Pipeline by Innovation Pharmaceuticals Inc, H2 2017 117 Psoriasis - Pipeline by Istesso Ltd, H2 2017 117 Psoriasis - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 118 Psoriasis - Pipeline by Johnson & Johnson, H2 2017 118 Psoriasis - Pipeline by Just Biotherapeutics Inc, H2 2017 119 Psoriasis - Pipeline by Kadmon Corp LLC, H2 2017 119 Psoriasis - Pipeline by Kang Stem Biotech Co Ltd, H2 2017 119 Psoriasis - Pipeline by KPI Therapeutics Inc, H2 2017 120 Psoriasis - Pipeline by Kymab Ltd, H2 2017 120 Psoriasis - Pipeline by Lead Pharma Holding BV, H2 2017 121 Psoriasis - Pipeline by LEO Pharma A/S, H2 2017 121 Psoriasis - Pipeline by Lupin Ltd, H2 2017 122 Psoriasis - Pipeline by Lycera Corp, H2 2017 122 Psoriasis - Pipeline by mAbxience SA, H2 2017 122 Psoriasis - Pipeline by Maruho Co Ltd, H2 2017 123 Psoriasis - Pipeline by Medestea Research & Production SpA, H2 2017 123 Psoriasis - Pipeline by MediGene AG, H2 2017 124 Psoriasis - Pipeline by Merck KGaA, H2 2017 124 Psoriasis - Pipeline by MetrioPharm AG, H2 2017 124 Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 125 Psoriasis - Pipeline by Momenta Pharmaceuticals Inc, H2 2017 125 Psoriasis - Pipeline by Mycenax Biotech Inc, H2 2017 126 Psoriasis - Pipeline by Nimbus Therapeutics LLC, H2 2017 126 Psoriasis - Pipeline by NovaLead Pharma Pvt Ltd, H2 2017 127 Psoriasis - Pipeline by Novan Inc, H2 2017 127 Psoriasis - Pipeline by Novartis AG, H2 2017 128 Psoriasis - Pipeline by Nuevolution AB, H2 2017 128 Psoriasis - Pipeline by Numab Innovation AG, H2 2017 129 Psoriasis - Pipeline by Oncobiologics Inc, H2 2017 129 Psoriasis - Pipeline by Orphagen Pharmaceuticals Inc, H2 2017 129 Psoriasis - Pipeline by Panacea Biotec Ltd, H2 2017 130 Psoriasis - Pipeline by Pfizer Inc, H2 2017 130 Psoriasis - Pipeline by Pharis Biotec GmbH, H2 2017 131 Psoriasis - Pipeline by Pharmedartis GmbH, H2 2017 131 Psoriasis - Pipeline by Phenex Pharmaceuticals AG, H2 2017 132 Psoriasis - Pipeline by Philogen SpA, H2 2017 132 Psoriasis - Pipeline by PinCell srl, H2 2017 132 Psoriasis - Pipeline by Principia Biopharma Inc, H2 2017 133 Psoriasis - Pipeline by Promius Pharma LLC, H2 2017 133 Psoriasis - Pipeline by Protalix BioTherapeutics Inc, H2 2017 133 Psoriasis - Pipeline by Prothena Corp Plc, H2 2017 134 Psoriasis - Pipeline by Provectus Biopharmaceuticals Inc, H2 2017 134 Psoriasis - Pipeline by Qilu Pharmaceutical Co Ltd, H2 2017 135 Psoriasis - Pipeline by RedHill Biopharma Ltd, H2 2017 135 Psoriasis - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 136 Psoriasis - Pipeline by Rigel Pharmaceuticals Inc, H2 2017 136 Psoriasis - Pipeline by Samumed LLC, H2 2017 137 Psoriasis - Pipeline by Sandoz International GmbH, H2 2017 137 Psoriasis - Pipeline by Sareum Holdings Plc, H2 2017 137 Psoriasis - Pipeline by SBI Biotech Co Ltd, H2 2017 138 Psoriasis - Pipeline by Shulov Innovative Science Ltd, H2 2017 138 Psoriasis - Pipeline by Sienna Biopharmaceuticals Inc, H2 2017 139 Psoriasis - Pipeline by Sigmoid Pharma Ltd, H2 2017 139 Psoriasis - Pipeline by Soligenix Inc, H2 2017 140 Psoriasis - Pipeline by Spherium Biomed SL, H2 2017 140 Psoriasis - Pipeline by Stemline Therapeutics Inc, H2 2017 140 Psoriasis - Pipeline by sterna biologicals Gmbh & Co KG, H2 2017 141 Psoriasis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 141 Psoriasis - Pipeline by Switch Biotech LLC, H2 2017 142 Psoriasis - Pipeline by Syntrix Biosystems Inc, H2 2017 142 Psoriasis - Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 143 Psoriasis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017 143 Psoriasis - Pipeline by TheraMAB LLC, H2 2017 143 Psoriasis - Pipeline by Tolero Pharmaceuticals Inc, H2 2017 144 Psoriasis - Pipeline by UCB SA, H2 2017 144 Psoriasis - Pipeline by Valeant Pharmaceuticals International Inc, H2 2017 145 Psoriasis - Pipeline by Vicore Pharma AB, H2 2017 145 Psoriasis - Pipeline by vTv Therapeutics Inc, H2 2017 146 Psoriasis - Pipeline by Wellstat Therapeutics Corp, H2 2017 146 Psoriasis - Pipeline by XBiotech Inc, H2 2017 147 Psoriasis - Pipeline by Yuhan Corp, H2 2017 147 Psoriasis - Dormant Projects, H2 2017 641 Psoriasis - Dormant Projects, H2 2017 (Contd..1), H2 2017 642 Psoriasis - Dormant Projects, H2 2017 (Contd..2), H2 2017 643 Psoriasis - Dormant Projects, H2 2017 (Contd..3), H2 2017 644 Psoriasis - Dormant Projects, H2 2017 (Contd..4), H2 2017 645 Psoriasis - Dormant Projects, H2 2017 (Contd..5), H2 2017 646 Psoriasis - Dormant Projects, H2 2017 (Contd..6), H2 2017 647 Psoriasis - Dormant Projects, H2 2017 (Contd..7), H2 2017 648 Psoriasis - Dormant Projects, H2 2017 (Contd..8), H2 2017 649 Psoriasis - Dormant Projects, H2 2017 (Contd..9), H2 2017 650 Psoriasis - Dormant Projects, H2 2017 (Contd..10), H2 2017 651 Psoriasis - Dormant Projects, H2 2017 (Contd..11), H2 2017 652 Psoriasis - Dormant Projects, H2 2017 (Contd..12), H2 2017 653 Psoriasis - Dormant Projects, H2 2017 (Contd..13), H2 2017 654 Psoriasis - Dormant Projects, H2 2017 (Contd..14), H2 2017 655 Psoriasis - Dormant Projects, H2 2017 (Contd..15), H2 2017 656 Psoriasis - Discontinued Products, H2 2017 657 Psoriasis - Discontinued Products, H2 2017 (Contd..1), H2 2017 658 Psoriasis - Discontinued Products, H2 2017 (Contd..2), H2 2017 659
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
